Risk of herpes zoster among adults in the United States initiating immunosuppressive therapy: A retrospective cohort study

Read full text Summarise with VIRAT
Authors: Justin Carrico, Yong Zhu, Andrea Steffens, Stephanie J Gallagher, Mary DuCharme, Nikita Stempniewicz, Justin Gatwood
Cited by: 0
References: 31

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: Patients immunosuppressed because of disease and/or therapy are at increased risk of developing herpes zoster (HZ) and related complications. However, HZ risk due to immunosuppressive medication remains underexplored across a broad spectrum of medication classes and conditions. OBJECTIVE: To estimate HZ risk among US adults initiating immunosuppressive therapy, across underlying conditions. METHODS: This retrospective study used administrative claims from the Optum Research Database (October 1, 2015, to December 31, 2022) to identify incident HZ diagnoses and the proportion of HZ with complications. Included patients were aged 18 years or older and had at least a 12-month baseline period of continuous enrollment with medical and pharmacy benefits. Analyses produced incidence rates (IRs) of HZ during periods of immunosuppression and nonimmunosuppression and compared patients initiating immunosuppressive therapy (immunosuppressed subcohort) vs matched controls who did not (nonimmunosuppressed subcohort). Cox regression analyses compared HZ hazards and a logistic regression model compared the difference in the occurrence of postherpetic neuralgia (PHN) following HZ diagnosis. RESULTS: < 0.001), and increased odds of PHN (adjusted odds ratio: 1.22 [95% CI = 1.14-1.31]) compared with the nonimmunosuppressed subcohort. CONCLUSIONS: Immunosuppressive medication use was associated with a higher risk of HZ and HZ-related complications. Measures to prevent HZ before immunosuppressive treatment initiation should be considered according to Advisory Committee on Immunization Practices recommendations and other professional organizations.

Fields of Study & Subjects

Herpesvirus Infections and Treatments Cytomegalovirus and herpesvirus research Virology and Viral Diseases

Publication details

Journal / source
Journal of Managed Care & Specialty Pharmacy
Volume
32
Issue
4
Pages
422–433
Publication date
26 March 2026
Language
EN